Video Shorts

1:25

Examining Alternative Splicing in Metastatic Bladder Cancer

5 months ago

Arshed Al-Obeidi, MD

0:52

Sarcomatoid vs Rhabdoid Dedifferentiation Outcomes in mccRCC

5 months ago

Akshit Chitkara, MD

Jason Westin, MD, explains the rationale for the ongoing evaluation of the novel CELMoD golcadomide (CC-99282) in the management of large B-cell lymphoma.

0:57

The Exploration of Golcadomide in LBCL Management

5 months ago

Jason Westin, MD

0:59

Important Upcoming Clinical Trials to Watch For in MCL

5 months ago

Tycel Phillips, MD

0:57

Subcutaneous Blinatumomab Demonstrates Promising Efficacy and Safety in First Patient With MPAL

5 months ago

Ashkan Emadi, MD, PhD

2:36

Real-World Data for Luspatercept in Lower-Risk MDS

5 months ago

Amer Zeidan, MBBS, MD

Guillermo Garcia-Manero, MD, breaks down the implications of the negative phase 3 VERONA trial in higher-risk MDS.

0:47

Implications of the Negative VERONA Trial of Venetoclax/Azacitidine in Higher-Risk MDS

5 months ago

Guillermo Garcia-Manero, MD

0:41

First TTFields Approval in Pancreatic Cancer Paves Way for More Multimodal Approaches

5 months ago

Vincent J. Picozzi, MD

1:46

Understanding the Therapeutic Team Delivery Concept in Oncology

5 months ago

Maurie Markman, MD

0:59

Reexamining the Definition of Postpartum Breast Cancer

5 months ago

Lisa Zhang, MD

3:41

OncLive News Roundup for the Week of 2/15

5 months ago

Courtney Flaherty(+1 more)

1:35

Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

6 months ago

Joel Neal, MD, PhD

1:41

Expert Insight on FDA Approval of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

6 months ago

Riley Kandel

Sagar Lonial, MD, FACP, FASCO on CELMoDs in Multiple Myeloma

1:10

The Evaluation of CELMoDs in Multiple Myeloma

6 months ago

Sagar Lonial, MD, FACP, FASCO

0:49

Highlighting the Potential Implications of the Ongoing INAVO123 Trial in HR+ Breast Cancer

6 months ago

Reva K. Basho, MD

0:59

STELLAR-303 Paves the Way for Potential FDA Approval of Immunotherapy-Based Regimen in MSS CRC

6 months ago

Anwaar Saeed, MD

1:32

Deconstructing Clinical Trial Interpretation for Fellows

6 months ago

Matthew Hadfield, DO

0:23

Starving Breast Cancer of Copper to Stop Disease From Spreading

6 months ago

Linda Vahdat, MD, MBA

0:25

Highlighting the Role of Pathologists in Breast Cancer Care

6 months ago

David L. Rimm, MD, PhD

0:31

The Importance of Patient Selection for Breast Cancer Treatment Optimization

6 months ago

Vikram C. Gorantla, MD

1:10

Boosting Gender Equity in the Oncology Workforce

6 months ago

Ana Velázquez Mañana, MD, MSc, FASCO

1:42

Tracing the Evolution of Multidisciplinary Cancer Care

6 months ago

Maurie Markman, MD

1:10

Go Behind-the-Scenes With OncLive at TCT 2026

6 months ago

Courtney Flaherty

0:44

Reducing Time to Breast Cancer Screening and Diagnosis

6 months ago

Martha Welman, MD

0:41

Exploring the Significance of a Pembrolizumab-Based Regimen in Ovarian Cancer

6 months ago

Emese Zsiros, MD, PhD

1:11

Targeting ENPP3 in RCC

6 months ago

Randy F. Sweis, MD

1:00

Prostate Cancer Topics to Watch at ASCO GU 2026

6 months ago

Mehmet Asim Bilen, MD

0:49

Bladder Cancer Abstracts to Watch at ASCO GU 2026

6 months ago

Jad Chahoud, MD, MPH, MHA

1:47

Zanzalintinib Plus Atezolizumab Is One Step Closer to FDA Approval in Previously Treated mCRC

6 months ago

Anwaar Saeed, MD

1:22

Kidney Cancer Abstracts to Watch at ASCO GU 2026

6 months ago

Jad Chahoud, MD, MPH, MHA

Video Shorts

Trending on OncLive

FDA Approves Rituximab Biosimilar for Hematologic Malignancies

Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026

Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC

Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC